- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05695222
Cutaneous Squamous Cell Carcinoma Staging Study
Comparison of the Prognostic Capacity of Existing Staging Systems for Cutaneous Squamous Cell Carcinoma
Cutaneous squamous cell carcinoma (CSCC) is the second most common form of skin cancer, and one of the most common cancers worldwide. The majority of CSCCs are easily removed by surgery and have excellent prognosis. However, a small subset has poor outcomes, including secondary spread in the body (metastasis) and death.
The investigators will look at existing CSCC in people from two UK dermatology centres. The investigators will then evaluate the accuracy of current staging systems in predicting risk of poor outcomes in people. The investigators hope that this project will improve the management of patients with CSCC by validating the predictive power of currently available histological staging classifications for cSCC. In the second stage of the study, The investigators will see whether better prediction tools can be found.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom
- Dr Emilia Peleva
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Over 18 years old with diagnosis of CSCC
Exclusion Criteria:
- Patients who decline for their data to be used for research purposes
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Retrospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence or metastasis
Time Frame: 4 years
|
Proportion of patients developing cutaneous squamous cell carcinoma locoregional recurrence, nodal or distant metastases
|
4 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 291683
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cutaneous Squamous Cell Carcinoma
-
Replimune Inc.Regeneron PharmaceuticalsActive, not recruitingCutaneous Squamous Cell Carcinoma | Advanced Cutaneous Squamous Cell Carcinoma | Metastatic Cutaneous Squamous Cell CarcinomaSpain, United States, France, Australia, Germany, Canada, Greece, Bulgaria, Italy, Poland
-
The Netherlands Cancer InstituteRecruitingCutaneous Squamous Cell CarcinomaNetherlands
-
Fondazione Melanoma OnlusActive, not recruitingCutaneous Squamous Cell CarcinomaItaly
-
H. Lee Moffitt Cancer Center and Research InstituteWithdrawnCutaneous Squamous Cell CarcinomaUnited States
-
Baptist Health South FloridaRegeneron PharmaceuticalsWithdrawnSquamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Advanced Squamous Cell CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 | Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck | Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage...United States
-
Incyte CorporationRecruitingCutaneous Squamous Cell CarcinomaUnited States, Korea, Republic of, Spain, Brazil, France, Turkey, Canada, Mexico, Chile, Australia, Romania, South Africa, Colombia, Finland, Hungary, Montenegro, New Zealand, Croatia, Netherlands, North Macedonia
-
Regeneron PharmaceuticalsSanofiRecruitingCutaneous Squamous Cell CarcinomaUnited States, Australia, Spain, Germany, Belgium, Italy, France, Japan, United Kingdom, Brazil, Canada, Greece, Ireland, New Zealand, Poland, Russian Federation
-
Corporacion Parc TauliHospital Clinic of BarcelonaCompletedCutaneous Squamous Cell Carcinoma
-
Ruhr University of BochumCompletedCutaneous Squamous Cell CarcinomaGermany
Clinical Trials on This is not an interventional study
-
University of British ColumbiaCompletedPain | Pain, Postoperative | Surgery | Orthopedic Procedures | Ambulatory Surgical Procedures | Nerve BlockCanada
-
Danone Asia Pacific Holdings Pte, Ltd.CompletedImmunologic Activity Alteration
-
University of California, RiversideUniversity of South FloridaUnknownAging | Hiv | IncentivesUnited States
-
University of OxfordImanova Centre for Imaging SciencesCompleted
-
University of AthensKing's College Hospital NHS Trust; Charite University, Berlin, Germany; University...Not yet recruiting
-
University of EdinburghNHS LothianCompleted
-
University College, LondonUniversity of Leeds; Medical Research Council; University of EdinburghUnknownDementiaUnited Kingdom
-
Shanghai Mental Health CenterCompletedSchizophrenia | Cognitive Dysfunction | Neuroimaging
-
University College, LondonUniversity of LeedsUnknownMultimorbidityUnited Kingdom